| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 444-446 |
| Seitenumfang | 3 |
| Fachzeitschrift | Cancer Cell |
| Jahrgang | 40 |
| Ausgabenummer | 5 |
| Frühes Online-Datum | 12 Apr. 2022 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 9 Mai 2022 |
Bibliographische Notiz
Funding Information:A.S.B. has received research support from Daiichi Sankyo and Roche; honoraria for lectures; consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, and Daiichi Sankyo; and travel support from Roche, Amgen, and AbbVie. T.F. has received honoraria for lectures and consultation or advisory board participation from the for-profit companies Merck Sharp & Dohme (MSD), Merck Darmstadt, Roche, Bristol-Myers Squibb, Accord, Sanofi, and Boehringer Ingelheim as well as travel support from Roche, MSD, and Bristol-Myers Squibb. The following for-profit companies have supported clinical trials and contracted research conducted by T.F. with payments made to his institution: MSD , Merck Darmstadt, Bristol-Myers Squibb. R.V. has received research grants from HVD Life-Sciences, Vienna, Austria; WORG Pharmaceuticals, Hangzhou, China; and Viravaxx AG, Vienna, Austria. He serves as consultant for Viravaxx AG and WORG. M.P. has received honoraria for lectures and consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, and Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by M.P. with payments made to his institution: Boehringer-Ingelheim, Bristol-Myers Squibb , Roche , Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline , and AbbVie . All other authors declare that they have no conflict of interest related to the present study.
Funding Information:
The authors thank Zoltan Vass for support with blood sampling. Author contributions: Study design and its implementation: M.J.M. M.M. P.G. J.M.B. W.T. A.C.B. M.G. A.S.B. S.L. L.G. T.B. H.H. W.W.L. M.R. S.T. T.F. R.V. D.F. and M.P.; Data analysis and interpretation: M.J.M. M.M. P.G. W.T. A.C.B. R.V. and M.P.; Manuscript writing and editing: M.J.M. P.G. W.T. A.C.B. R.V. and M.P. All authors read and approved the final version of the manuscript. D.F. and M.P. contributed equally and are co-last authors. M.J.M. and M.P. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Funding/Role of funder statement: This study was funded by the research budget of the Medical University of Vienna, the budget of the S?dtiroler Sanit?tsbetrieb and partly by a grant from the Federal State of Lower Austria, Grant: Danube Allergy Research Cluster (Danube ARC, R.V.). The funding organizations had no role/influence in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. A.S.B. has received research support from Daiichi Sankyo and Roche; honoraria for lectures; consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, and Daiichi Sankyo; and travel support from Roche, Amgen, and AbbVie. T.F. has received honoraria for lectures and consultation or advisory board participation from the for-profit companies Merck Sharp & Dohme (MSD), Merck Darmstadt, Roche, Bristol-Myers Squibb, Accord, Sanofi, and Boehringer Ingelheim as well as travel support from Roche, MSD, and Bristol-Myers Squibb. The following for-profit companies have supported clinical trials and contracted research conducted by T.F. with payments made to his institution: MSD, Merck Darmstadt, Bristol-Myers Squibb. R.V. has received research grants from HVD Life-Sciences, Vienna, Austria; WORG Pharmaceuticals, Hangzhou, China; and Viravaxx AG, Vienna, Austria. He serves as consultant for Viravaxx AG and WORG. M.P. has received honoraria for lectures and consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, and Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by M.P. with payments made to his institution: Boehringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, and AbbVie. All other authors declare that they have no conflict of interest related to the present study.
Funding Information:
The authors thank Zoltan Vass for support with blood sampling. Author contributions: Study design and its implementation: M.J.M., M.M., P.G., J.M.B., W.T., A.C.B., M.G., A.S.B., S.L., L.G., T.B., H.H., W.W.L., M.R., S.T., T.F., R.V., D.F., and M.P.; Data analysis and interpretation: M.J.M., M.M., P.G., W.T., A.C.B., R.V., and M.P.; Manuscript writing and editing: M.J.M., P.G., W.T., A.C.B., R.V., and M.P.. All authors read and approved the final version of the manuscript. D.F. and M.P. contributed equally and are co-last authors. M.J.M. and M.P. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Funding/Role of funder statement: This study was funded by the research budget of the Medical University of Vienna , the budget of the Südtiroler Sanitätsbetrieb and partly by a grant from the Federal State of Lower Austria, Grant: Danube Allergy Research Cluster (Danube ARC, R.V.). The funding organizations had no role/influence in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Systematik der Wissenschaftszweige 2012
- 302 Klinische Medizin